JP7863509B2 - 新たな組換え溶解素及びグラム陰性細菌感染の治療におけるその使用 - Google Patents

新たな組換え溶解素及びグラム陰性細菌感染の治療におけるその使用

Info

Publication number
JP7863509B2
JP7863509B2 JP2022554850A JP2022554850A JP7863509B2 JP 7863509 B2 JP7863509 B2 JP 7863509B2 JP 2022554850 A JP2022554850 A JP 2022554850A JP 2022554850 A JP2022554850 A JP 2022554850A JP 7863509 B2 JP7863509 B2 JP 7863509B2
Authority
JP
Japan
Prior art keywords
gram
seq
negative bacteria
chimeric protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022554850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517245A (ja
JP2023517245A5 (cg-RX-API-DMAC7.html
Inventor
マルティネス ロベルト ディエス
アレイサーガ マリア モラレス
Original Assignee
テラム セラピューティクス エセ.エレ.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テラム セラピューティクス エセ.エレ. filed Critical テラム セラピューティクス エセ.エレ.
Publication of JP2023517245A publication Critical patent/JP2023517245A/ja
Publication of JP2023517245A5 publication Critical patent/JP2023517245A5/ja
Priority to JP2025231925A priority Critical patent/JP2026041893A/ja
Application granted granted Critical
Publication of JP7863509B2 publication Critical patent/JP7863509B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01028—N-Acetylmuramoyl-L-alanine amidase (3.5.1.28)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022554850A 2020-03-11 2021-03-11 新たな組換え溶解素及びグラム陰性細菌感染の治療におけるその使用 Active JP7863509B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025231925A JP2026041893A (ja) 2020-03-11 2025-12-04 新たな組換え溶解素及びグラム陰性細菌感染の治療におけるその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20382177 2020-03-11
EP20382177.2 2020-03-11
EP20382254.9 2020-03-31
EP20382254 2020-03-31
PCT/EP2021/056264 WO2021180892A1 (en) 2020-03-11 2021-03-11 New recombinant lysin and its use in the treatment of gram-negative bacterial infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025231925A Division JP2026041893A (ja) 2020-03-11 2025-12-04 新たな組換え溶解素及びグラム陰性細菌感染の治療におけるその使用

Publications (3)

Publication Number Publication Date
JP2023517245A JP2023517245A (ja) 2023-04-24
JP2023517245A5 JP2023517245A5 (cg-RX-API-DMAC7.html) 2024-03-21
JP7863509B2 true JP7863509B2 (ja) 2026-05-21

Family

ID=74859480

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554850A Active JP7863509B2 (ja) 2020-03-11 2021-03-11 新たな組換え溶解素及びグラム陰性細菌感染の治療におけるその使用
JP2025231925A Pending JP2026041893A (ja) 2020-03-11 2025-12-04 新たな組換え溶解素及びグラム陰性細菌感染の治療におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025231925A Pending JP2026041893A (ja) 2020-03-11 2025-12-04 新たな組換え溶解素及びグラム陰性細菌感染の治療におけるその使用

Country Status (8)

Country Link
US (2) US12655409B2 (cg-RX-API-DMAC7.html)
EP (1) EP4118192A1 (cg-RX-API-DMAC7.html)
JP (2) JP7863509B2 (cg-RX-API-DMAC7.html)
CN (2) CN115605587B (cg-RX-API-DMAC7.html)
AU (1) AU2021236351A1 (cg-RX-API-DMAC7.html)
CA (1) CA3175024A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022011291A (cg-RX-API-DMAC7.html)
WO (1) WO2021180892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria
CN114774391B (zh) * 2022-03-09 2023-03-14 华南农业大学 一种抗大肠杆菌的噬菌体内溶素及其应用
WO2024231498A1 (en) * 2023-05-09 2024-11-14 BioNTech SE Intravaginal formulations of gardnerella endolysins
FR3149209B1 (fr) * 2023-06-02 2026-04-03 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique
WO2024246325A1 (en) * 2023-06-02 2024-12-05 L'oreal Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol
CN121420063A (zh) * 2023-06-30 2026-01-27 国立大学法人 冈山大学 可穿透革兰氏阴性菌外膜的多肽、包含所述多肽的抗菌蛋白、抗菌剂或消毒剂、药物组合物、以及抗菌剂组合物或消毒剂组合物
TW202541833A (zh) * 2023-12-12 2025-11-01 德商拜恩技術股份公司 包含內溶素之組合物及其用途
CN118420716B (zh) * 2024-05-28 2025-10-31 青岛农业大学 一种多肽125、包含多肽125的生物材料及应用
WO2026139534A1 (en) * 2024-12-24 2026-07-02 Telum Therapeutics, S.L. Antibacterial peptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002959A2 (en) * 2008-07-03 2010-01-07 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria
PL2445515T3 (pl) 2009-06-26 2016-10-31 Środki przeciwdrobnoustrojowe
JP5847081B2 (ja) 2009-08-24 2016-01-20 カトリック ユニバーシテイト ルーベン ケイ.ユー. ルーベン アール アンド ディー エンドリシンOBPgpLYS
RU2614114C2 (ru) 2010-09-17 2017-03-22 Текнифар-Индустриа Текника Фармасьютика, С.А Бактериофаги, фаговые пептиды и способы их применения
GB201018518D0 (en) 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
BR112016030580B1 (pt) 2014-06-26 2023-12-19 The Rockefeller University Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas
ES2934714T3 (es) 2015-09-17 2023-02-24 Contrafect Corp Polipéptidos de lisina activos contra bacterias Gram-negativas
KR20240162610A (ko) * 2017-04-03 2024-11-15 사시나파스 컴퍼니 리미티드 조작된 그람-음성 엔도리신
CN111420037B (zh) * 2020-03-26 2022-05-10 中国农业科学院饲料研究所 噬菌体裂解酶Lysep3在制备广谱抗菌药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Database GenPept,Accession No. YP_009284326,[online],2018年08月13日,[検索日2025.02.25],インターネット<URL: https://www.ncbi.nlm.nih.gov/protein/1070100424?sat=48&satkey=135615780>
J. Microbiol.,2017年,Vol. 55,No. 5,p. 403-408

Also Published As

Publication number Publication date
US20260226444A1 (en) 2026-08-06
JP2023517245A (ja) 2023-04-24
JP2026041893A (ja) 2026-03-10
US12655409B2 (en) 2026-06-16
MX2022011291A (es) 2022-12-08
WO2021180892A1 (en) 2021-09-16
CN115605587A (zh) 2023-01-13
CN115605587B (zh) 2026-02-13
AU2021236351A1 (en) 2022-10-06
US20230138922A1 (en) 2023-05-04
EP4118192A1 (en) 2023-01-18
CN121422198A (zh) 2026-01-30
CA3175024A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
CN115605587B (zh) 新型重组溶素及其在治疗革兰氏阴性菌感染中的用途
AU2018201931B2 (en) Antimicrobial Agents
RU2724545C2 (ru) Полипептиды лизина, активные против грамотрицательных бактерий
JP6034188B2 (ja) 抗微生物剤
CN102575240B (zh) 新的细胞内溶素OBPgpLYS
EP2635676B1 (en) Novel endolysin
EP2702070B1 (en) New antimicrobial agents
CN102197132B (zh) 抗微生物剂
JP2016208985A (ja) バイオフィルムの低減方法
TW201239095A (en) Antimicrobial agents
KR102503567B1 (ko) 신규한 엔돌리신
CN115851690B (zh) 一种用于杀灭动物源病原菌的杂合抗生酶及其应用
HK40013452A (en) Novel endolysin
HK40013452B (en) Novel endolysin
HK1224571B (en) Antimicrobial agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221104

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20221104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240311

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260511

R150 Certificate of patent or registration of utility model

Ref document number: 7863509

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150